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Summary 
Cytotoxic T lymphocytes (CTL) recognize antigenic peptides bound to major histocompatibility 
complex class I antigens on the cell surface of virus-infected cells. It is believed that the majority 
of peptides originate from cytoplasmic degradation  of proteins  assumed to be mediated by the 
"20S" proteasome. Cytosolic peptides are then translocated, presumably by transporters associated 
with antigen processing (TAP-1 and -2), into the lumen of the endoplasmic reticulum (ER) 
where binding and formation of the ternary complex between heavy chain, 32-microglobulin 
(32m) and peptide occurs. In this study, we have analyzed and compared the phenotype of two 
mutant cell lines, the thymoma cell line RMA-S and a small lung carcinoma cell line CMT.64, 
in order to address the mechanism that underlies the antigen processing deficiency of CMT.64 
ceils. Unlike RMA-S cells, vesicular  stomatitis virus (VSV)-infected  CMT.64 cells are not recognized 
by specific CTL. Interferon 3: (IFN-'y) treatment of CMT.64  cells restores the ability of these 
cells to process and present VSV in the context of K  b. We show that although CMT.64  cells 
express a low level of 432m, the recognition by VSV-specific CTL is not restored by increasing 
the amount of B2m synthesized in CMT.64 cells. In addition, we find that CMT.64 cells express 
moderate levels of K b heavy chain molecules, but most of it is unstable and rapidly degraded 
in the absence of IFN-'y treatment. We infer that the antigen processing deficiency does not 
lie at the level of/32m or K  b production. We find also that the mRNAs for both TAP-1 and 
-2 are present in RMA and RMA-S cells but are absent in uninduced CMT.64 cells. Upon IFN-'y 
induction, both mRNAs are highly expressed in CMT-64 cells. In addition,  we find that the 
low molecular mass polypeptides  2 and 7, and additional  components of the proteasome are 
induced by IFN-~/in CMT-64 cells. Finally, introduction of the rat TAP-1 gene in CMT.64 
cells restores CTL recognition of VSV-in_fected  cells. These results indicate that a TAP-1 homodimer 
may translocate peptides in the ER and explain partially the CMT.64  defect and the RMA-S 
phenotype. These findings link a dysfunction in the transport and/or generation  of antigenic 
peptides to the capacity of tumor cells to evade immunosurveillance and provide a unique model 
system to dissect this phenomenon. 
M 
HC class I molecules are normally expressed at the cell 
surface as ternary complexes formed by a heavy chain 
of 46 kD, a light chain called Bu-microglobulin (32m)  1 of 
R. Gabathuler and G. Reid contributed  equally  to this work. 
1 Abbreviations used in thistmper: 132m, 32-microglobulin;  ER, endoplasmic 
reticulum; LMP, low molecular  mass polypeptide;  MOI, multiplicity  of 
infection; N, nucleocapsid; TAP, transporter associated with antigen 
processing; VSV, vesicular  stomatitis virus. 
12 kD, and a peptide composed of 8-10 amino acids (1-4). 
Formation of the ternary complex is thought to involve trans- 
port into the lumen of the endoplasmic reticulum (ELL) of 
peptides generated by protein degradation in the cytoplasm 
(5-7). The study of mutant cell lines selected for their low 
expression of MHC class I molecules at the cell surface has 
provided insights into the molecular events required for an- 
tigen processing. These studies have allowed the identification 
of two genes located in the MHC region which encode pro- 
teins of the ATP binding cassette (ABC) family. These genes, 
called transporters associated with antigen processing 1 and 
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tides from the cytoplasm to the lumen of the ER (8-17). 
Two other MHC linked genes, low molecular mass polypep- 
tides 2 and 7 (LMP-2 and -7) (18),  are components of the 
proteasome, a cytoplasmic multicatalytic protease complex, 
that is likely responsible for some aspects of protein degrada- 
tion for antigen processing (19-25). 
The mouse mutant lymphoma cell line RMA-S expresses 
low levels of class I molecules at the cell surface compared 
to the wild-type RMA cells (26, 27). Influenza virus-infected 
RMA-S cells present influenza peptides in the context of D s 
molecules ineffidently and are only weakly recognized by 
specific CTL (27). Transfection with the putative transporter 
gene, TAP-2, complements this deficiency (28, 29). The en- 
dogenous TAP-2 gene of RMA-S cells was shown to contain 
a point mutation that introduces a stop translation codon 
resulting in an incomplete and defective TAP-2 protein (30). 
Despite the defective TAP-2 protein in ILMA-S cells, anti- 
genic peptides from vesicular stomatitis virus (VSV) bypass 
the defect and are presented to specific CTL by K b molecules 
in RMA-S cells (31,  32). The VSV-nucleocapsid (N) pep- 
tide, VSV-N 52-59,  was shown earlier to be the major pep- 
tide presented by K ~ molecules on VSV-infected cells  (1). 
The presence of the wild-type TAP-1 protein in RMA-S cells 
may be sufficient for translocation of the VSV-N 52-59 pep- 
tide to the ER lumen (28-30).  Alternatively, the VSV-N 52-59 
peptide may not need a functional transporter for transport 
into the lumen of the EK. Expression of minigene-encoded 
viral peptide epitopes in T2 cells (33) and in vitro translation 
and translocation using microsomes from T2 cells (34) sup- 
port this contention. 
A  separate class of antigen-processing variants are those 
in which the assembly and the surface expression of MHC 
class I molecules are entirely inducible by IFN-~/(35). For 
example, in the small lung carcinoma cell line CMT.64, rec- 
ognition by influenza virus-specific CTL does not take place 
unless induced with IFN-3~ (36).  The very low amount of 
all proteasome components present in uninduced CMT.64 
cells is presumed to be responsible for their phenotype (19). 
Exogenous influenza peptides can bind to D b molecules on 
CMT.64  cells  and complement recognition by influenza- 
specific CTL (36).  In addition, we have found that ~2m and 
the VSV-N 52-59 peptides added exogenously to these cells 
complement recognition by VSV-specific CTL restricted to 
K b (37).  The amount of B2m and of heavy chains synthe- 
sized in these cells may limit the amount of MHC class I 
expression on the cell surface (37). A dysfunction of the puta- 
tive peptide transporters and/or in the generation of the pep- 
tide may be responsible for the CMT.64 phenotype which 
may represent a mechanism to downregnlate MHC class I 
expression, a feature common to many carcinomas. 
RMA, RMA-S, and CMT.64 cells originate from the same 
strain of mice, C57B1/6, and therefore should have the same 
transporter genes with identical properties regarding the pep- 
tide  delivery to  D b and  K b molecules unless  mutated or 
downregulated (26,  35). This therefore gives us the oppor- 
tunity to examine the constituents of antigen processing in 
a controlled system. In this paper, we show that RMA-S and 
CMT.64 cells have a different phenotype regarding VSV an- 
tigen processing and presentation with K b molecules. We 
have followed the expression of heavy and light chains, trans- 
porters (TAP-1 and -2), and proteasome components (LMP-2 
and -7) in RMA, ILMA-S,  and CMT.64 IFN-3, induced or 
uninduced cells  and we have compared the phenotype of 
RMA-S and CMT.64 cells regarding antigen presentation in 
the context of K b molecules. These data revise the interpre- 
tation  of  the  molecular  basis  of  the  antigen-processing 
deficiency in the carcinoma cells CMT.64.  In addition, we 
have reintroduced several  components of the antigen processing 
machinery in order to examine their ability to complement 
the CMT.64  phenotype. 
Materials  and Methods 
Animals and Viruses.  C57Bl/6 mice were bred at the Univer- 
sity of British Columbia breeding facility. Mice were 6-12-wk-old 
and were maintained in accordance  with the guidelines of the Cana- 
dian Coundl on Animal  Care. VSV was grown on Veto cell 
monolayers. Vaccinia and a human flon (hflzm) vaccinia recom- 
binant were generous gifts from Dr. J. Yewdell (National Insti- 
tutes of Health,  Bethesda, MD). 
Cell Lines and Antibodies.  CMT.64  cells (H-2b), graciously 
provided by Dr. L. M. Franks (Imperial Cancer Research Fund, 
London, UK), RMA, and RMA-S ceils  were maintained in DMEM 
supplemented with 10% heat inactivated FCS, 20 mM Hepes, 2 
mM glutamine, and antibiotics. The mAbs used were as follows: 
142-23.3 anti-H-2 K b, 28-11-5s anti-H-2 D b (r  +  r  28-14-8s, 
anti-H-2 D b (a3), and BBM.1 against human Bzm 08). A rabbit 
antiserum against hfl2m (39), against exon-8 of H-2K  b (40), and 
against rat proteasome (20) were also used. 
Transfection.  Transfection  of  CMT.64 cells  with rat eDNA TAP-1 
in the pHb APt-1 neo expression vector (kindly provided by Dr. 
G. Butcher, AFRC, Institute of Animal Physiology, Cambridge, 
UK)  was  achieved by  lipofection  (Lipofectin;  GIBCO  BRL, 
Gaithersburg, MD) asing 10/~g of  DNA. Selection  was in 1 mg/ml 
G418 (GIBCO BILL). Positive clones were selected and screened 
by Northern blotting for expression of the rat TAP-1 gene. The 
results obtained with a representative clone are reported (see Fig. 
9). As negative controls, clones obtained from a vector DNA trans- 
fection were analyzed by Northern blotting. The results obtained 
with a representative done are reported (see Fig. 9). 
Flow CTtometry AnalTsis.  To determine the ceU surface expres- 
sion of MHC class I molecules, we used FACS  |  analysis (Becton 
Dickinson & Co.,  Mountain  View, CA). RMA, RMA-S, and 
CMT.64 cells were treated with or without recombinant murine 
IFN-3~ at 150-300 U/ml (Genzyme Cytokine Research Products, 
Cambridge, MA) for 48 h. The cells were collected and incubated 
overnight in medium without FCS, with VSV-N 52-59 peptide 
(50/~M) and/or hfl2m (2.5 p,g). Peptides were purchased from the 
University of Victoria, Peptide Synthesis Facility (Victoria, BC, 
Canada). The cells  were subsequently  removed  from culture, washed, 
and incubated with 1:50 dilution of 142-23.3 ascites, or 200 ~1 of 
cell culture supernatant from 28-11-5s and 28-14-8s cells for 45 min 
on ice. After two washes, the cells were incubated with 100/~1 
of 1:20 dilution of  goat anti-rabbit, or goat anti-mouse FITC-con- 
jugated secondary antibody for another 45 rain on ice. The samples 
were then fixed in paraformaldehyde (1.5% in PBS) and analyzed 
on a FACScan  |  cell sorter using the FACScan  |  program (Becton 
Dickinson & Co.). Values reported in Table 1 are in linear terms 
representing the average  of 5,000 cells. The corrected value (minus 
the value without first antibodies) is reported. 
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electric Focusin~ and SDS-PAGE.  Cells  were  washed  in  MEM 
medium without methionine I h before labeling and labeled with 
150 #Ci/ml  of [35S]methionine  for 1 h  or as indicated.  For the 
pulse--chase  experiments, cells were labeled for 15 min and then 
chased with normal medium containing an excess of cold methio- 
nine. Labeled cells were solubilized with I ml of 20 mM Tris-HC1, 
pH 7.6, containing 0.12 M NaC1, 4 mM MgCI2, and 1% NP-40; 
PMSF (a protease inhibitor) was added to a final concentration of 
20 #g/ml before use. After 15 min on ice, particulate material was 
removed by centrifugation.  The supernatant was used for immu- 
noprecipitation of labeled antigens.  Labeled solubilized antigens were 
first precleared with 2 #1 of normal rabbit serum for 45  rain at 
4~  followed by 50 #1 of protein A-Sepharose (1:1 in solubiliza- 
tion buffer) for another 45 min at 4~  Protein A-Sepharose was 
removed by a quick centrifugation. The precleared supernatant was 
reacted with the appropriate antibody or immune serum for 1 h 
at 4~  35  #1 of protein A-Sepharose was added and incubation 
continued  for a further 30 rain.  After centrifugation,  the beads 
were washed twice with 0.2%  NP-40 in  10 mM Tris-HC1,  pH 
7.5, 0.15 M  NaC1, and 2 mM EDTA, once with 0.2%  NP-40 in 
10 mM Tris-HC1, pH 7.5, 0.5 M NaC1, 2 mM EDTA, and finally 
with 10 mM Tris-HC1, pH 7.5. One-dimensional isoelectric focusing 
was performed as previously described (41).  SDS-PAGE  was car- 
fled out  as described (42). 
CTL Response  Against VSV-infected,  IFN-7-induced Cells.  KMA, 
KMA-S, and CMT.64 cells were treated with or without  IFN-'y 
at 200 U/ml for 48 h. They were subsequently washed three times 
with PBS and treated with VSV at a multiplicity of infection (MOI) 
of 5 in 0.5 ml,ofmedium for 1 h. The cultures were then incubated 
in a total of 3 ml of growth medium for an additional 4-8 h  (as 
indicated),  to allow infection to proceed.  Single  cell suspensions 
were treated with 100 #Ci 51Cr per 106 cells for 2 h in KPMI 1640 
supplemented with L-glutamine and penicillin/streptomycin in the 
absence of fetal bovine serum (FBS) and sodium bicarbonate. Al- 
ternatively, CMT.64 cells were infected with vaccinia (V), and/or 
vaccinia-hfl2m  (Vb2) at an MOI of 5 for 5 h followed by superin- 
fection with VSV (MOI, 5) for an additional 4 h. The cells were 
washed 3 x  and subsequently incubated at 104 cells per well in 96- 
well plates with the effector population at ratios of 100:12.5. Mock- 
infected cells were used as negative controls.  The effector CTL popu- 
lation was generated by immunizing C57B1/6 mice with VSV at 
5  x  106-1  x  107 Tissue culture infection dose 50% in the foot 
pads and ears.  On day 5 after immunization,  the draining lymph 
nodes (retropharyngeal and popliteal) were harvested and cultures 
initiated at 4  x  106 cells/ml in a total volume of 5 ml in 6-well 
plates. The culture medium consisted of RPMI-1640 supplemented 
with 5  x  10 -s M 2-ME, 10% heat-inactivated  FBS, sodium pyru- 
vate, penicillin,  streptomycin, L-glutamine, Hepes, sodium bicar- 
bonate, and 50% NCTC-109. Cultures were incubated for 3 d at 
37~  and 5% CO2 in the absence of exogenous stimulation. The 
SlCr-release was measured by ~r compugamma counter (model 1282 
CS; LKB Instruments, Gaithersburg, MD) and the specific S~Cr- 
release calculated as [(experimental  -  media control)/(total  -  media 
control)] x  100%.  The spontaneous release  never exceeded  17% 
of the maximum release. 
RNA Extraction  and Northem Analysis.  Total cellular KNA was 
prepared from cell lines using guanidinium isothiocyanate (GITC). 
Briefly, the cells were lysed in 4 M GITC then centrifuged (130,000 g 
for 16 h at 23~  through a cushion of cesium chloride. After eth- 
anol precipitation,  the purified RNA was resuspended in diethyl 
pyrocarbonate-treated H20.  10 #g of each sample was loaded and 
separated on a 1% agarose gel containing 2.2 M formaldehyde. The 
gel was blotted  onto  Hybond N  (Amersham Corp.,  Arlington 
Heights, IL) and U/V fixed before hybridization. The 32P-labeled 
probes used for hybridization were as follows: MTP1 and MTP2 
(TAP-1 and -2 respectively,  kindly provided by Dr. GeoffButcher), 
prepared by random priming, and an oligonucleotide specific for 
fl:actin labeled by terminal transferase.  Hybridization was carried 
out  at  42~  in  buffer containing  0.4  M  Na2HPO4,  50%  for- 
mamide, and  7% SDS.  Several washes were performed at 42~ 
under conditions of increasing stringency and the filter exposed 
to X-OMAT AR film (Eastman Kodak) overnight. 
Results and Discussion 
The small lung carcinoma cell line, CMT.64,  was shown 
to express and assemble MHC  class I  molecules on the cell 
surface after IFN-3, treatment (35-37). To understand the mo- 
lecular deficiency in antigen processing of CMT.64 cells, the 
Figure  1.  CTL recognition ofVSV-infected KMA, RMA-S, CMT.64 
IFN-q/induced or uninduced cells. Targets were treated with or without 
IFN-3, for 48 h before infection with VSV. (.4) Kepresentative  experiment 
using RMA and RMA-S cells as targets. (B) Equivalent experiment with 
CMT.64 cells (C). All cells were infected with VSV at a MOI of 10 for 
4 h. IPN'3' treatment is denoted with a +  sign after the cell line designa- 
tion.  Spontaneous release did not c:~:eed 15%. 
1417  Gabathuler et al. Table  1.  Peptides (p), hfl2m (l~2m), and IFN-',/  (IFN)  Treatment Modifies the Conformation of K ~ and D b Expressed on  the Cell 
Surface of RMA,  RMA-S,  and CMT.64  Cells 
Antibodies 
Treatment  142-23.3  28-11-5s  BBM.1 
Cell lines  IFN  p  B2m  K b spec.  D b spec.  h3zm spec. 
Experiment  1 
Experiment  2 
Experiment  3 
CMT  64 
RMA 
RMA-S 
-  -  -  5*  3  ND 
-  +  +  8  5  ND 
+  -  -  26  58  ND 
+  +  +  35  53  ND 
+  -  -  346  430  6 
+  +  -  606  449  4 
+  -  +  438  549  406 
+  +  +  780  515  606 
+  -  -  12  4  14 
+  +  -  10  1  14 
+  -  +  10  2  76 
+  +  +  41  2  262 
RMA  -  -  -  164  173  1 
-  +  +  242  182  274 
RMA-S  -  -  -  12  2  1 
-  +  +  70  2  86 
* Arbitrary fluorescense units. 
contrasting phenotypes of CMT.64 cells versus RMA-S cells 
were analyzed. VSV-infected RMA-S cells are recognized as 
ef~dently as the wild-type RMA cells with or without IFN-3~ 
treatment (Fig. 1 A), in comparison to VSV-infected CMT.64 
cells which are not recognized by specific CTL unless induced 
by IFN-3' (Fig. 1 B). It should be noted that RMA-S, RMA, 
Figure  2.  Amount  of  Bzm 
synthesized in  RMA,  RMA-S, 
and CMT.64 IFN-~/induced or 
uninduced cells. Cells were  labeled 
for  2  h  with  [3sS]methionine, 
lysed, immunoprecipitated  with a 
rabbit anti-hB2m serum, and ana- 
lyzed  by SDS-PAGE.  Radioactive 
proteins are detected after 6-h ex- 
posure to a XAR film. CMT.64 
cells treated (+) or not (-) with 
IFN-% R.MA and RMA-S cells 
were used. (Left) The migration 
of the molecular weight marker. 
and CMT.64 cells  are equally permissive  to infection with 
VSV as indicated by the number of infective particles pro- 
duced after infection measured by a TCIDs0 assay (data not 
shown).  We conclude that uninduced CMT.64 cells have a 
different  or additional  deficiency to the functionally defec- 
tive peptide  transporter  TAP-2 present  in  RMA-S cells. 
Previous experiments have demonstrated that treatment of 
mutant  cells  with  exogenous peptides  and/or  human 32m 
can stabilize "empty" class I molecules at the cell surface (27, 
43, 44). RMA, RMA-S, and CMT.64 cells uninduced or in- 
duced with IFN-3/were treated  overnight with exogenous 
peptides VSV-N 52-59 at 50/zM in the presence or absence 
of human 32m.  VSV-N  52-59 peptides  and fl2m synergis- 
tically increase the expression of the K b conformational spe- 
cific epitope recognized by 142.23.3 mAb (Table 1) on RMA 
and RMA-S cells.  VSV-N 52-59 peptides  specifically affect 
the stability and the conformation of the K b molecules and 
have no effect on D b molecules.  Human  32m binds  to K b 
and D b molecules, which are detected by BBM.1 (anti-human 
32m mAb), and appears to stabilize heavy chains before they 
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against CMT.64  cells. Infected  CMT.64  cells  were  su- 
perinfected with vaccinia and vacdnia-/32m recom- 
binant (/.q"b2),  vaccinia  and VSV (  WS V), or vaccinia- 
/$2m VSV (Vb2-VSV) in FBS-free  media (MOI 3) for 
up to an additional  12 h. (Inset) The level  of ~2m syn- 
thesized  is shown  after  immunoprecipitation  with the 
anti-hBzm rabbit serum. CMT.64 cells treated with 
peptide  VSV-N52-59 at 500 pM for 2 h (CMT+p) was 
used as the positive control, whereas mock-treated 
CMT.64 cells (CMT+  - - - ) were used as the nega- 
tive control. Radioactivity  released is the average of 
quadruplicate wells. Spontaneous  release did not ex- 
ceed 16%. 
can disassemble at the cell surface. A stabilizing effect is not 
seen after CMT.64 treatment with peptides or ~2m alone. 
Additional treatment of CMT.64 cells with IFN-3' is required 
for high expression of K b and D b conformation-specific epi- 
topes on the cell surface (Table 1). We conclude that CMT.64 
cells express much lower amounts of empty class I molecules 
at the cell  surface  than RMA-S cells. 
Earlier work (45) has shown that the presence of B2m and 
peptides within the lumen of the EK is necessary for efficient 
assembly and cell surface expression  of MHC class I mole- 
cules. Fig. 2 shows that CMT.64 cells express a low amount 
of endogenous ~n  (Fig. 2, lane 1). IFN-'y-induced CMT.64 
cells express a much higher amount of/$2m, which is com- 
parable to the level expressed in RMA and RMA-S cells (Fig. 
2,  lanes 2-4).  To investigate the effect of ~2m in CMT.64 
cells, we have used a recombinant vaccinia virus to increase 
the amount of endogenous/~2m (Fig. 3, inset). Elevating the 
amount of/$2m synthesized using a recombinant vaccinia 
virus  does  not  restore  CTL recognition  of VSV-infected 
CMT.64 cells (Fig. 3). We conclude that increasing expres- 
sion of B2m does not induce presentation of VSV-N  pep- 
tides in the context of K  b molecules.  The CMT.64 antigen- 
processing phenotype is not caused by the low amount of 
endogenous B2m. 
Our previous paper (37) has shown that MHC class I heavy 
chains are synthesized in significant amounts in CMT.64 cells, 
but very few molecules are reaching the cell surface unless 
these cells are treated with IFN-'y. Here the transport of K b 
and D b molecules was examined after a pulse-chase labeling 
of CMT.64, RMA and RMA-S cells and SDS-PAGE analysis 
of the immunoprecipitated material (for K b, 142.23.3 mAb 
was  used  and for  D b,  28-14-8s,  an ot3-specific  mAb  was 
used)  (Fig.  4).  Despite a similar amount of K b molecules 
synthesized in RMA and RMA-S cells (Fig. 4, 0-h chase time), 
only low amounts of K b are processed  to a higher molec- 
ular weight form, indicative of the level of transport which 
accounts for the surface expression  of K b in RMA-S cells. 
The processed  form is resistant to endoglycosidase H diges- 
tion (data not shown) indicating transport out of the ER. The 
observation that much more fl~n is immunoprecipitated  with 
K b molecules than with D b molecules in RMA-S cells (Fig. 
4) may indicate that the mAb 142.23.3  only recognizes the 
assembled  form, heavy and light chains of K b molecules, 
whereas the mAb 28-14-8s recognizes the a3 region of D b 
molecules.  The presence  of a functional TAP-1  protein in 
RMA-S cells (30) may be sufficient to enable some peptides 
to cross the ER membrane and bind a small number of K b 
molecules allowing them to go to the cell surface. Also, pep- 
tides with lower affinity for K b molecules may bind and aid 
the molecules to assemble  and go to the cell surface where 
they dissociate.  Much fewer mature processed D b molecules 
are detected in RMA-S cells after 4-h chase  (Fig.  4).  This 
may indicate a lower affinity of D b for fl2m and/or fewer 
peptides available for D b binding. In RMA cells, K b mole- 
cules are processed within 1 h. In comparison, D b molecules 
are processed  more slowly (2 h) (Fig.  4).  These results are 
in agreement with the relative transport rate of K b and D b 
in RMA-S cells. IFN-'y treatment augments the synthesis 
of heavy chains causing more K b and D b molecules to be 
transported to the cell surface of RMA and RMA-S cells. 
The rate of transport of K  b and D b molecules is not affected 
by IFN-3' treatment in RMA and RMA-S cells. In contrast, 
no  K b molecules are  detected in CMT.64  cells  using the 
142.23.3 mAb. This mAb, as indicated earlier, may not recog- 
nize the unassembled and peptide-free heavy chains of K b 
molecules (Fig. 4). To address this issue, we have used a rabbit 
anti-exon 8 serum directed against a conformation-independent 
epitope recognizing a peptide in the cytoplasmic tail of H-2K  b 
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molecules in uninduced  and IFN-'y-induced CMT.64 cells. Cells were la- 
beled with [3SS]methionine and chased in an excess of cold methionine 
for the times indicated in hours.  Solubilized antigens  were immunopre- 
eipitated  with a rabbit  anti-exon  8 of H-2K  a serum recognizing the cy- 
tophsmic tail of free and assembled K  b heavy chains. (Top) Treatments; 
(left) migration of the molecular weight markers. Radioactive proteins are 
detected  after 4-d exposure  to a RPN-30 film  (Amersham  Corp.). 
Figure 4.  IntraceUular transport  of MHC class I molecules, D b and K  b. 
Cells were labeled with [3SSlmethionine and chased in an excess of cold 
methionine for the times indicated  in hours.  Solubilized  antigens  were 
immunoprecipitated  with 142.23.3 mAbs for K  b or 28-14-8s mAbs for 
D b. (~p) Treatments;  (/eft) migration of the molecular  markers.  Coim- 
munoprecipitation  of the heavy chains (46 hi) and 3zm (12 kD) can be 
seen for all cells e~cept for CMT.64 uninduced  cells. Radioactive proteins 
are detected after 8-d exposure  for RMA-S cells and 4 d for RMA and 
CMT.64 cells to a XAR film. 
molecules (40)  to  detect  and follow the processing of K b 
molecules in uninduced or IFN-3~-induced CMT.64 cells. In 
uninduced CMT.64 cells,  K b molecules are detectable early 
after synthesis (Fig. 5, 0-, 0.5-, and 1-h chase time), but are 
unstable and mostly degraded after 8-h chase with very few 
molecules processed to a higher molecular weight (Fig.  5, 
8-h chase time). In induced cells, K b molecules are synthe- 
sized in  higher  amounts  and  a  greater proportion  of the 
molecules are processed to a higher molecular weight (Fig. 
5). We cannot explain the decrease in the amount of material 
immunoprecipitated by this antiserum during the chase. A 
loss or degradation of  the epitope recognized  by the antiserum 
during transport is possible.  Furthermore, D b molecules are 
also  synthesized and are then degraded or denatured (Fig. 
4). In uninduced CMT.64 cells, no processed D b molecules 
can be detected even after 4-h chase.  Only treatment with 
IFN-3' results in higher expression, increased transport, and 
increased transport rate of K b and D b molecules in CMT.64 
cells. Thus, components necessary for the assembly and trans- 
port of K b heavy chains and 32m are induced by IFN-'y in 
CMT.64 cells, whereas similar induction does not significantly 
alter the transport of D b and K b in RMA or RMA-S cells. 
This indicates that CMT.64 cells are likely deficient in com- 
ponents necessary for MHC class I assembly which differ from 
the TAP-2 defect in RMA-S cells. 
Next, in order to assay the function of the MHC class I 
molecules, the CTL recognition of CMT.64 cells IFN-3' in- 
duced or uninduced and RMA-S cells treated with exoge- 
nous peptides was examined (Fig.  6).  In a dose-dependent 
manner, RMA-S and CMT.64 IFN-,y-treated cells were 10,000 
times more sensitive than CMT.64 cells to killing by specific 
CTL  after 2-h  treatment with exogenous peptides.  These 
results provide evidence for the low expression of peptide- 
receptive MHC class I molecules on the surface of  uninduced 
CMT.64 cells. In the dose-response on RMA-S cells, a max- 
imum of 15,000  peptide molecules per call were needed to 
achieve 50% killing by specific CTL, whereas a lower threshold 
of 150 molecules per cell resulted in the release of 5-10% 
of S~Cr. These data may be explained by a high amount of 
receptive molecules or high af~nity of the MHC class I mol- 
ecules for the peptide on the surface of RMA-S and IFN- 
y-induced CMT-64 cells. Under the conditions of our assay, 
where there is no exogenous 32m,  the exogenously added 
peptides likely stabilize the empty K b molecules which ar- 
rive at the cell surface of RMA-S before they dissociate from 
B2m (37, 45). The low amount of empty K b transported in 
uninduced CMT.64 cells would explain the difference in sen- 
sitization to  exogenous peptides. 
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Figure 6.  VSV-N  52-59 peptide 
dose-response  in CTL recognition. 
CMT.64 cells (CMT), CMT.64 + 
IFN-~/  (CMT  +  IFN-'7),  and 
RMA-S  cells  (RMA-S)  were  treated 
with pepfide  N52-59  at the concen- 
trations indicated. The radioactivity 
released  by specific  CTL ~ognition 
and lysis was measured and repre- 
sented as indicated  in Materials and 
Methods. Radioactivity  released  is 
the average of quadruplicate wells. 
Spontaneous release  did not e~xeed 
13%. 
The  results  shown in  Figs.  2-6  indicate  that  despite its 
lower expression, Bzm alone is not responsible for the lack 
of antigen presentation in CMT.64 cells. In addition, K b and 
D b molecules are synthesized in these cells but very few are 
transported to the cell surface where they bind exogenously 
added peptides. Besides heavy and light chains,  peptides are 
necessary for the efficient assembly of MHC class  I  mole- 
cules in the ER (10-12,  27).  We have looked at the possi- 
bility that the absence of components responsible for the gener- 
ation and transport of these peptides within the ER may be 
responsible  for the CMT.64  phenotype. 
A putative peptide transporter,  presumed to be composed 
Figure 7.  Northern  blot anal- 
),sis of total cellular RNA from 
RMA,  ILMA-S, and  CMT.64 
IFN-~/ induced and  uninduced 
cells. 10 #g of cytoplasmic  RNA 
from CMT.64 (lanes 1 and 2), 
RMA (lanes  3 and 4), and RMA-S 
(lanes 5  and 6) cells IFN-7-in- 
duced  (+)  or  uninduced (-) 
were analyzed.  TAP-l,  TAP-2,  and 
13-actin probes were hybridized 
with the membrane. The radio- 
activity bound to specific RNA 
sequences is detected after over- 
night exposure  of the membrane 
to a XAR film. 
of a heterodimer of two half-ABC type transporters  called 
TAP-1 and -2, has been implicated in translocating peptides 
into the ER for MHC class I assembly (15,  16).  To charac- 
terize  the  difference  of phenotypes  between  RMA-S  and 
CMT.64 cells, the expression of TAP-1 and -2 genes in these 
cell  lines was examined.  In Fig.  7,  Northern  blot analysis 
shows that uninduced CMT.64 cells do not express a detect- 
able amount of TAP-1 and -2 mRNA and that the amount 
of these mRNAs is highly increased after IFN-3, treatment 
of these cells. In addition, we show that no major difference 
exists between TAP-1 and -2 gene expression in RMA-S and 
RMA cells (Fig.  7) and that  IFN-3/treatment  only margi- 
nally affects TAP-1 and -2 expression in these cells. The amount 
of actin mRNA gives an indication of the near equal amount 
ofmRNA loaded on the gel for Northern blotting. The IFN-3, 
inducibility of TAP-1 and -2 has been previously demonstrated 
in mouse tissues (46), however, this has not been examined 
in RMA, RMA-S, or CMT.64 cells before this present study. 
The results reported here show that the TAP-1 and -2,genes 
are IFN-3' inducible in CMT.64 cells and to a lesser degree 
in RMA and RMA-S cells.  The  absence of TAP-1  and -2 
mRNA expression in CMT.64  cells likely causes a lack of 
antigenic  peptides in the EK for binding  to and assembly 
of MHC class  I molecules. This results in the nonrecogni- 
tion of VSV-infected CMT.64 cells. In contrast, RMA-S cells 
express a functional TAP-1 molecule that may aid peptides 
to cross the ER membrane. This would explain the assembly 
and transport of MHC class I in RMA-S cells and their CTL 
recognition  after VSV infection.  The lack of TAP-1 and -2 
in uninduced CMT.64 cells may be one of the factors respon- 
sible for the phenotype of CMT.64 cells characterized by the 
1421  Gabathuler et al. Figure 8.  Two-dimensional gd analysis of proteasome components from 
RMA, RMA-S, and CMT.64 IFN-'y-induced or uninduced  cells. Cells 
were labded for 2 h with [3SS]methionine. Solubilized antigens were im- 
munoprecipitated  with a rabbit anti-rat proteasome  serum and analyzed 
after isoelectric focusing in a first dimension  and 10-15%  SDS-PAGE in 
a second dimension.  The radioactive proteins  are detected after 10-d ex- 
posure to a XAR film. (~p) Treatment  of the cells; (right)  acidic side of 
the gel; and (left)  basic fide of the gal. The migration of the molecular 
weight markers is indicated on the left. The missing proteins are indicated 
by an arrow  and are numbered.  Proteins  numbered 1 and  7 correspond 
to LMP-7 and LMP-2,  respectively. 
formation of unstable and inefficiently  transported MHC dass 
I complexes. 
Before concluding that TAP deficiencies are the likely or 
only defects in CMT.64 cells, we decided to examine the pres- 
ence of  proteasome components in these cells. Viral peptides 
are thought to be generated in the cytoplasm by the protea- 
some (19-25) before crossing the ElL membrane. The pro- 
teasome components are likely key players in antigen pro- 
cessing which could be absent in these cells. A rabbit anti-rat 
proteasome serum was used which recognizes the mouse pro- 
teasome. After immunoprecipitation of the proteasomes, the 
different component LMP produced in these mouse cells (Fig, 
8) can be analyzed by two-dimensional gel electrophoresis. 
Two-dimensional gel analysis  of  immunoprecipitations reveals 
that the major components of  the proteasome are not affected 
by IFN-3' treatment of CMT.64 cells but that seven compo- 
nents,  including LMP-2  and -7,  are missing in uninduced 
CMT.64 cells. According to the results of others (47), the 
proteins numbered 1 and 7 in Fig. 8 correspond to LMP-7 
and -2, respectively. LMP-2, -7, and five other components 
of the proteasome are upregulated slightly by IFN-y in RMA 
and RMA-S cells and are induced from a state of an unde- 
tectable expression to a higher detectable level of expression 
in IFN-7-treated CMT.64 cells (Fig. 8). LMP-7 (Fig. 8) is 
particularly  highly induced in CMT.64  cells treated with 
IFN-% These components are not recognized in any of the 
cell lines used in this study by nonimmune  rabbit serum (data 
not shown). These results contrast the results of  others which 
suggested that CMT.64 express a low level of all proteasome 
components (18) and these new results indicate that these 
induced proteasome  components may affect the activity of 
the proteasome and allow the generation of the VSV-N pep- 
tides in induced CMT.64 cells. Recent data (48, 49) suggest 
that LMP-2 and -7 may not be necessary for influenza virus 
antigen presentation in mutant cells  transfected  with the TAP-1 
and -2 genes. 
Our results show that IFN-3' treatment in addition to in- 
ducing transcription  of TAP-1 and -2 gene also upregnlates 
the synthesis of seven components of the proteasomes, in- 
cluding LMP-2 and -7. Others describe that components in 
addition to LMP-2 and -7 are upregulated in Hela cell pro- 
teasomes by IFN-'y treatment (24, 47). However, as these 
cells are functionally wild type, the functional ramification 
of this regulation has not been addressed. Furthermore, as 
LMP-2 and -7 are first synthesized as precursor proteins which 
are cleaved  into smaller products (47), it is possible that some 
of  the five  additional proteins missing from uninduced CMT.64 
cells are precursor  proteins  of LMP-2  and -7. 
Consideration  of the accumulated data regarding antigen 
processing in RMA-S and CMT.64 cells leads to the conten- 
tion that a functional TAP-1 protein homodimer alone may 
facilitate the transport of the VSV-N 52-59 peptide from the 
cytosol to the ER lumen where binding to the heavy chains 
takes place. An alternative explanation  is that this peptide 
does not require a transporter for translocation across the ER 
membrane  but is not generated in the CMT.64 cells. To more 
dearly define the defect affecting the recognition of VSV- 
infected CMT.64 cells by specific CTL, we have introduced 
the rat TAP-1 gene in CMT.64 cells. In Fig. 9, we show that 
VSV-infected TAP-1 positive CMT.64  cells are recognized 
by specific  CTL. On the contrary, VSV-infected  CMT.64 cells 
transfected with the vector DNA only are not recognized 
by specific CTL. This result  indicates that TAP-1 alone is 
suificient for restoration of  VSV recognition in CMT.64 cells 
and explains the RMA-S phenotype and its apparent "leaki- 
ness" regarding VSV presentation (31, 32). TAP-1 alone may 
1422  Role for TAP-1 Alone in Antigen Processing Figure  9.  CMT 64 (CMT), CMT 64 transfected  with TAP-1 (CMT 
TAP/), and CMT.64 transfected  with the vector only  (CMT Vec) were 
infected with or without VSV for 8 h at a MOI of 5, or treated with 
N52-59 peptide for 2 h at 500 pM (50% dose-response). Spontaneous 
release did not exceed 12%. 
be sufficient for VSV presentation in tLMA-S cells and in trans- 
fected CMT.64 cells and may form a homodimer capable of 
translocation of spedfic peptides into the lumen of the EIL. 
Further studies are underway to define the role of transporter 
homodimers and heterodimers in peptide uanslocation during 
virus infection (Reid, G., lL. Gabathuler, G. Kolaitis, and 
W. A. Jeffcries,  manuscript in preparation). In addition to 
transporters, the difference in the tLMA-S and CMT.64 pheno- 
type may be explained at one level by the higher amount of 
viral peptides generated in RMA-S cells. As reported recently, 
a more dticient protein degradation machinery is present in 
ceils with proteasome containing aU the LMP components 
(including LMP-2 and -7) (50, 51). This would cause a higher 
quantity of peptides to be expressed  in cells expressing all 
the components of the proteasome. It is interesting to note 
that one may assume that a total repression of the expression 
of  both LMPs and TAPs localized in the same region of class 
II may be suflficient for avoiding any expression of class I on 
the cell surface. This may be very important for some cancer 
cells (38,  52,  53) by providing a method by which tumor 
ceils avoid immunosurveiUance. 
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